Clinical trials: Non-functioning Pituitary Adenomas
Non-functioning Pituitary Adenoma
Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
This study assessed pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.
- Trial name
- Passion I (NCT01283542)
- Testing
- Pasireotide LAR
- Where
- 7 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Non-functioning Pituitary Adenomas, Prolactinomas
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
There are no available medical treatment options for patients with non-functioning pituitary adenomas (NFPA) or with resistant prolactinomas to dopamine agonists (DA) who are not cured by surgery.
- Trial name
- NCT01620138
- Testing
- Pasireotide, cabergoline
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Pituitary Tumor, ACTH-producing Pituitary Tumour
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph…
- Trial name
- PASSILCORT (NCT02749227)
- Testing
- Pasireotide LAR
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University